Pioglitazone Receives New Warnings Due to Slight Increase in Bladder Cancer Risk
By Independent Staff Writer
The health review of the Type 2 diabetic drug, pioglitazone, performed by the European Medicines Agency, confirmed the drug remains a valid treatment option for certain patients while acknowledging a minimal increase in bladder cancer risk. The caveat in the conclusions of the health review centered upon advising physicians to use care and caution when prescribing the drug. The results further stated that those who are prescribed pioglitazone—especially those who take relatively high doses or have taken the drug for longer than a year—must have their overall health monitored closely. Exclusion of certain higher risk groups, such as the elderly is also recommended.
Assessing Risk Factors in Potential Patients
Physicians are warned to screen patients carefully, and avoid prescribing pioglitazone to those who have a history of bladder cancer or who currently have bladder cancer. Patients with uninvestigated macroscopic haematuria are also advised against taking pioglitazone. As stated, age carries a specific risk, as the elderly are already more likely to develop bladder cancer based solely on age. Because of this an alternative diabetes medication with less risk in this area should be prescribed. Patients taking Actos should undergo regular 3-6 month reviews to assess and monitor benefit vs. risk.
Sources of Information
In making its safety recommendations, the Committee for Medicinal Products for Human Use considered results of pre-clinical and clinical studies as well as spontaneous reports and epidemiological studies. The Scientific Advisory Group on Diabetes also weighed in with advice regarding pioglitazone. The CHMP concluded from this array of evidence that while there is a slight increase in bladder cancer among those taking pioglitazone, this risk exists primarily in those who take the drug for long periods of time or in relatively high doses. That being said, those who take the drug for a short amount of time cannot be excluded from the risks.
Further Research Indicated
The CHMP has indicated that further research and controlled studies are necessary to fully explore the risk of bladder cancer in those taking pioglitazone as compared to those who take other diabetic drugs or those who take no diabetic drugs. It is expected that the issue of whether prolonged use or high cumulative doses are more likely to cause bladder cancer will be more clearly addressed in subsequent studies.
The Bottom Line
Both the SAG and CHMP agree that among patients who will not receive adequate treatment from other diabetic drugs—and who are neither elderly nor have a history of bladder cancer—pioglitazone is still considered the best therapy. While patients must be carefully screened and monitored, the benefits of pioglitazone still outweigh the potential risks.
DISCLAIMER: All cases are based on individual circumstances and the facts pertaining to each case, and the outcome for any particular case depends on a variety of factors. None of the information provided on this website should suggest or guarantee a particular result for any given case. None of the information provided on this website should be construed in any way as legal advice. Further, none of the information provided on this website should suggest or imply the formation of an attorney-client relationship in any capacity whatsoever.
|
|
|
|
|
|
|
|
|
|
Free Consultation
|
|
Receive an immediate response to your request.
|
|
|
|
|
|
|
Recent Articles and Publications
|
|
|
|
April 25, 2012
|
|
Recovering From Actos-Related Bladder Cancer: Part 1of 2: How Can I Prevent a Recurrence?
|
|
Actos, or pioglitazone, is a prescription medicine used in the treatment of Type-2 diabetes and works by sensitizing cells to the pancreas-produced hormone known as insulin. Insulin is used by the body to regulate the amount of sugar or glucose in the body therefore when cells are more sensitive to insulin, sugar in the blood naturally moves more easily into cells.
|
|
Full Story
|
|
|
|
|
April 23, 2012
|
|
Recovering From Actos-Related Bladder Cancer: Part 2 of 2: What All Actos Users Should Know:
|
|
Actos, a drug used in the treatment of Type 2 Diabetes has been shown to carry a risk of bladder cancer, particularly among those who are elderly or who have taken the drug in higher doses or for extended periods of time (longer than one year). Although the drug has not yet been recalled by the FDA, it has fallen under intense scrutiny and has been pulled from the French and German markets.
|
|
Full Story
|
|
|
|
|
March 03, 2012
|
|
Actos Discussions Part 2: Dangers of the Drug
|
|
Links to higher heart disease rates have been associated with the use of Actos, and, in fact, Actos may cause as many heart problems as GlaxoSmithKline’s drug, Avandia. The American Heart Association reported that studies showed patients taking either diabetes drug were at least four times as likely to experience heart attacks, heart failure or even death.
|
|
Full Story
|
|
|
|
No article available
|
|
|
|
|
|